Loading...
Market
What will be the outcome of the first large-scale clinical trial for lamivudine in treating Alzheimer's by the end of 2024?
2
Resolution / Starting Odds
Statistically significant improvement • 25%
No significant difference • 25%
Worse outcomes • 25%
Trial terminated early • 25%
Results published in peer-reviewed medical journals or official clinical trial results
Story
New Technique Models Late-Onset Alzheimer's Using Patient-Derived Neurons, Lamivudine Shows Promise
Aug 1, 2024, 09:08 PM
Researchers at Washington University School of Medicine have developed a new technique to model late-onset Alzheimer's disease using patient-derived neurons. This method involves transforming skin cells into induced pluripotent stem cells and then into neurons, which accurately replicate the disease's features. The study, published in Science Magazine, identifies the role of retrotransposons, or 'jumping genes,' in Alzheimer's disease. This approach allows scientists to study the effects of aging on Alzheimer's without the need for brain biopsies. Additionally, the drug lamivudine has shown to reduce Alzheimer's effects in lab-grown neuron models.
View original story
Similar markets
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial not completed • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
Trial discontinued • 25%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trials halted • 25%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
Not started • 25%
Yes • 50%
No • 50%
Successful with significant efficacy • 25%
Successful with moderate efficacy • 25%
Successful with minimal efficacy • 25%
Unsuccessful • 25%
Yes • 50%
No • 50%
Successful completion of Phase 1 • 25%
Partial success in Phase 1 • 25%
Failure in Phase 1 • 25%
No results announced • 25%
Successful • 25%
Partially successful • 25%
Unsuccessful • 25%
Trial not completed • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Russia • 25%
Europe (excluding Russia) • 25%
North America • 25%
Asia (excluding Russia) • 25%
